EVALUATION OF LACTATE DEHYDROGENASE (LDH) AS A MARKER FOR LORLATINIB EFFICACY IN PATIENTS WITH ADVANCED ALK-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC).

被引：0
|
作者：
Dinh, M. [1 ]
Pithavala, Y. [1 ]
Chen, J. [1 ]
机构：
[1] Pfizer, San Diego, CA USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2022年 / 111卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
P-053
引用
收藏
页码：S19 / S19
页数：1
相关论文
共 50 条
  • [21] Efficacy of Lorlatinib in Advanced ALK-Positive NonSmall Cell Lung Cancer Patients in Thailand: A Multicenter Study
    Maneenil, K.
    Baisamut , T.
    Sitthideatphaiboon, P.
    Payapwattanawong, S.
    Korphaisarn, K.
    Suksombooncharoen, T.
    Vinayanuwattikun, C.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S642 - S643
  • [22] Evaluation of the effect of crizotinib (CRZ) on the QT interval in patients with ALK-positive non-small cell lung cancer (NSCLC)
    Tan, Weiwei
    Wilner, Keith D.
    Lanzalone, Silvana
    Polli, Anna
    Zierhut, Matthew L.
    Nickens, Dana
    O'Byrne, Kenneth J.
    Blackhall, Fiona H.
    Shaw, Alice T.
    Salgia, Ravi
    Jaime, Jesus Correl
    Kim, Dong-Wan
    CANCER RESEARCH, 2015, 75
  • [23] ESTIMATING THE BUDGET IMPACT OF CRIZOTINIB FOR ALK-POSITIVE ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IN ARGENTINA
    Wang, B.
    Furnback, W.
    Xuan, J.
    VALUE IN HEALTH, 2014, 17 (03) : A74 - A74
  • [24] CLINICAL EXPERIENCE WITH CRIZOTINIB IN SPECIAL POPULATIONS WITH ADVANCED ALK-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC)
    Ahn, M-J
    Crino, L.
    Solomon, Ben
    Zhou, Caicun
    Ou, Sai-hong I.
    Selaru, P.
    Cohen, D. P.
    Bartlett, C. H.
    Kim, Dong-wan
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (11) : S490 - S491
  • [25] Impact of lorlatinib on patient-reported outcomes in patients with advanced ALK-positive or ROS1-positive non-small cell lung cancer
    Peters, Solange
    Shaw, Alice T.
    Besse, Benjamin
    Felip, Enriqueta
    Solomon, Benjamin J.
    Soo, Ross A.
    Bearz, Alessandra
    Gadgeel, Shirish M.
    Lin, Chia-Chi
    Kao, Steven
    Seto, Takashi
    Masters, Elizabeth T.
    Abbattista, Antonello
    Clancy, Jill S.
    Thurm, Holger
    Reisman, Arlene
    Peltz, Gerson
    Camidge, D. Ross
    LUNG CANCER, 2020, 144 : 10 - 19
  • [26] Treatment of ALK-Positive Non-Small Cell Lung Cancer
    Bang, Yung-Jue
    ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2012, 136 (10) : 1201 - 1204
  • [27] Chinese perspectives on clinical efficacy and safety of alectinib in patients with ALK-positive advanced non-small cell lung cancer
    Yu, Hui
    Sun, Si
    Hu, Xingjiang
    Xia, Jinjing
    Wang, Jialei
    Chen, Haiquan
    ONCOTARGETS AND THERAPY, 2019, 12 : 6481 - 6495
  • [28] Comparison of cardiovascular effects of crizotinib and chemotherapy in patients (pts) with ALK-positive (+) advanced non-small cell lung cancer (NSCLC)
    Wilner, K.
    Usari, T.
    Polli, A.
    Kim, E.
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (04) : S133 - S133
  • [29] Treating ALK-positive non-small cell lung cancer
    Ziogas, Dimitrios C.
    Tsiara, Anna
    Tsironis, Georgios
    Lykka, Maria
    Liontos, Michalis
    Bamias, Aristotelis
    Dimopoulos, Meletios-Athanasios
    ANNALS OF TRANSLATIONAL MEDICINE, 2018, 6 (08)
  • [30] Monitoring of ALK Fusions and Mutations in Advanced ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients
    Mezquita, L.
    Remon, J.
    Nicotra, C.
    Noerholm, M.
    Brinkmann, K.
    Planchard, D.
    Jovelet, C.
    Auclin, E.
    Flinspach, C.
    Hurley, J.
    Skog, J.
    Gazzah, A.
    Caramella, C.
    Adam, J.
    Lacroix, L.
    Auger, N.
    Friboulet, L.
    Soria, J.
    Besse, B.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1954 - S1955
12345